![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
References
- United States Renal Data Systems, the concise 2008 annual data report. USRDS 2008 Annual Data Report: atlas of chronic kidney disease & end-stage renal disease in the United States. http://www.usrds.org/2008/usrds_booklet_08.pdf. Accessed 08 May 2012
- United States Renal Data Systems. USRDS 2008 Annual Data Report: atlas of chronic kidney disease & end-stage renal disease in the United States. http://www.usrds.org/2008/pdf/V2_11_2008.pdf. Accessed 08 May 2012
- Società Italiana di Nefrologia. Registro Italiano di Dialisi e Trapianto. http://www.sin-ridt.org/sin-ridt.org.htm. Accessed 07 May 2012
- Rombol`a G. Dialysis for everybody? At any cost? J Nephrol 2002;15(6 Suppl):S33-S42
- Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 1994;23:229-36
- Marco MP, Craver L, Betriu A, et al. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int Suppl 2003;63:S111-4
- Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, Q6 and cardiovascular disease in hemodialysis patients: the USRDS Waves 1, 3, and 4 Study. J Am Soc Nephrol 2005;16:1788-93
- Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18
- Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67:1179-87
- Block GA, Port FK. Re-evaluation of risks associated with hyperphsphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Disease 2000;35:1226-37
- Mazzaferro S, Brancaccio D, Messa P, et al. Management of secondary hyperparathyroidism in Italy: results of the Italian FARO survey. J Nephrol. 2011 Mar-Apr;24(2):225-35
- Mazzaferro S, Cozzolino M, Marangella M, et al. Calcimimetics, phosphate binders, vitamin D and its analogues for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology. G Ital Nefrol 2007 (24 Suppl)37:107-24. Italian. PubMed PMID: 17347960
- Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 2001;38(5 Suppl):S45-50